Focus: Inventprise is a vaccine-focused biotechnology company headquartered in Redmond, WA, developing novel vaccines for infectious diseases including pneumococcal disease, group B streptococcal infections, and shigella. The company operates at mid-cap biotech scale with 51-200 employees.
Profile data last refreshed 6h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Inventprise to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Inventprise
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Inventprise's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Pneumonia Market Set to Witness Robust Growth During the Forecast Period (2026-2036), Driven by Advancing Therapeutics and Rising Disease Burden | DelveInsight - PR Newswire UK
Pneumonia Market Set to Witness Robust Growth During the Forecast Period (2026-2036), Driven by Advancing Therapeutics and Rising Disease Burden | DelveInsight PR Newswire UK
New 25-Valent Pneumococcal Vaccine Shows Promise in Global Disease Coverage - Drug Topics
New 25-Valent Pneumococcal Vaccine Shows Promise in Global Disease Coverage Drug Topics
Vaccine Makers Curtail Research and Cut Jobs - The New York Times
Vaccine Makers Curtail Research and Cut Jobs The New York Times
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles
Macro vaccine-sector headwinds combined with zero open roles and pre-revenue status elevate organizational stability risk; due diligence on funding status and burn rate recommended.
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications